- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
| home:special:hospitals_emergencies [09.17.2017] – [Minimizing risks of hospitalization] sallieq | home:special:hospitals_emergencies [09.17.2017] – [If hospitalized] + telmisartan should never be taken by someone in a hospital setting, it will render the patient vulnerable to increased infection sallieq | ||
|---|---|---|---|
| Line 51: | Line 51: | ||
| * Have someone with you who will be assertive enough to advocate for you. | * Have someone with you who will be assertive enough to advocate for you. | ||
| * If you are incapable, a member of your family or your health care agent should be allowed to participate in these decisions. Make sure they are familiar with the MP guidelines. | * If you are incapable, a member of your family or your health care agent should be allowed to participate in these decisions. Make sure they are familiar with the MP guidelines. | ||
| - | * Do not attempt to explain the MP to emergency medical personnel. Just show them the notice for emergency medical personnel described above. | + | * Do not attempt to explain the MP to emergency medical personnel. Just show them the notice for emergency medical personnel described above. |
| * The focus of treatment should be on stabilizing the acute problem with standard methods that will not compromise the MP and which will allow you to return home as soon as possible rather than be admitted to the hospital. | * The focus of treatment should be on stabilizing the acute problem with standard methods that will not compromise the MP and which will allow you to return home as soon as possible rather than be admitted to the hospital. | ||
| * Question everything and ask your advocate to take notes. | * Question everything and ask your advocate to take notes. | ||
| Line 93: | Line 93: | ||
| * Patients on the MP should not take **nimesulide** (Aulin / Mesulid / Nimed). It could possibly cause internal bleeding. | * Patients on the MP should not take **nimesulide** (Aulin / Mesulid / Nimed). It could possibly cause internal bleeding. | ||
| * rivaroxaban (Xarelto) increases the risk of bleeding and can cause serious or fatal bleeding. **A specific antidote for rivaroxaban is not available**. | * rivaroxaban (Xarelto) increases the risk of bleeding and can cause serious or fatal bleeding. **A specific antidote for rivaroxaban is not available**. | ||
| + | * telmisartan should never be taken by someone in a hospital setting, it will render the patient vulnerable to increased infection | ||
| * Refuse all antifungals. Refuse all vitamin D supplementation in food, IV fluids or tube feedings. | * Refuse all antifungals. Refuse all vitamin D supplementation in food, IV fluids or tube feedings. | ||
| * Alert staff to any other food allergies. | * Alert staff to any other food allergies. | ||
home/special/hospitals_emergencies.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.